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Abstract 
Hutchinson-Gilford Progeria is an accelerated aging disorder caused by a de novo point 
mutation in the LMNA gene which codes for an intermediate filament of the nuclear lamina 
called lamin A. The point mutation at c.1824C>T causes a 50-amino-acid deletion that 
removes the binding site for Zmpste24, a metalloprotease responsible for defarnesylating 
prelamin A and producing mature lamin A. Without the ability to be defarnesylated, the 
mutated protein, called progerin, is more lipophilic and has a myriad of cytotoxic effects. 
As cardiovascular disease is the most common cause of death in HGPS patients, it is 
important for both healthcare professionals and the scientific community to understand 
how the cellular pathologies induced by progerin contribute to vascular pathology. This 
review identified four categories of vascular pathology and explains the cellular 
pathologies that contribute to them. These categories are vascular smooth muscle cell 
(VSMC) loss and lack of replenishment, vascular calcification, atherosclerosis, and 
contractility. It also addresses relevant treatment options for patients with the disease.  
  
HGPS VASCULAR REVIEW  4 
Overview 
 The presence of progerin gives rise to numerous pathologies in HGPS cells and 
patients. This review identifies these key models of pathology. With vascular disease 
being the leading cause of death for HGPS patients, those pathologies of specific 
importance to vascular disease are identified. These pathologies fall into four broad 
categories: vascular smooth muscle cell loss, vascular calcification, development of 
atherosclerosis, and factors that affect heart muscle contractility. Lastly, the history of 
treatments to date for HGPS symptoms is covered. 
Introduction 
 Progerin is a mutated version of the lamin A protein normally found in the 
structural layer of the nucleus, the nuclear lamina. This protein is found in increasing 
levels as normal human cells undergo the aging process (McClintock et al., 2007), but is 
found in relatively high levels in almost all tissue types in patients with HGPS with few 
exceptions. The properties of progerin that functionally distinguish it from lamin A are 
subtle but devastating. 
Progerin is a result of a single point mutation in the LMNA gene that results in a 
cryptic splice site. The machinery that cuts the RNA then cleaves 50 amino acids from 
the protein. The deletion of these amino acids includes the deletion of the binding site for 
Zmpste24, a metalloprotease responsible for post-translational modification of prelamin 
A. Without its binding site, Zmpste24 cannot remove the lipophilic farnesyl tail on 
prelamin A (Eriksson et al., 2003). The resulting protein, progerin, is more lipophilic than 
wild-type lamin A (Moiseeva et al., 2016).  
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Vascular Disease 
The number one cause of death for HGPS patients is vascular disease. While 
many factors contribute to vascular disease in HGPS patients, this review groups them 
into four broad categories: VSMC loss and the inability to replenish them, vascular 
calcification, factors contributing to atherosclerosis, and defects in electrical conduction 
and contractility of the heart tissue. While the focus of vascular disease is on disease of 
the aorta in HGPS patients, a study by Silvera et al. showed that the extent of vascular 
disease reaches past the aorta and into intracranial arteries. In the study, 92% of their 
patients exhibited narrowing of the internal carotid artery. Other patterns of narrowing 
were found in the anterior cerebral artery, middle cerebral artery, and posterior cerebral 
artery. The study also showed evidence of stroke in 60% of patients, with the mean age of 
first stroke being 6.8 years. Most of these strokes were clinically silent (Silvera et al., 
2013). These patterns of cerebrovascular events may encourage the scientific community 
to conduct more research on how the factors promoting vascular disease affect 
intracranial arties as well as the large somatic arteries.  
VSMC Loss and Lack of Replenishment 
Both autopsies of HGPS patients and analysis of mouse models of HGPS show 
extensive loss of vascular smooth muscle cells (VSMCs) within the vessel walls. These 
cells are instead replaced by ECM materials like proteoglycans (Villa-Bellosta et al., 
2013). Several factors contribute to VSMC loss in a progerin-dependent manner, 
including DNA damage leading to mitotic defects, chemical modifications of chromatin, 
nuclear response to strain, and telomere dysfunction, while factors that prevent the 
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replenishment of VSMCs include decreased cell motility and lack of stem cell self-
renewal. Acute loss of VSMCs as opposed to other cell lineages can be attributed in part 
to higher levels of progerin in this cell lineage as compared to other cell types (Zhang et 
al., 2011).  
DNA Damage 
A wealth of knowledge has been assembled on DNA damage in HGPS cells, but 
this review will highlight some common themes ranging from increased reactive oxygen 
species (ROS) levels to the inability for DNA damage repair proteins to correctly 
assemble or even enter the nucleus at all. Sufficient DNA damage alone is enough to 
cause cells to either stop replicating or induce apoptosis, which would contribute to 
overall VSMC loss. 
When the function of mitochondrial complexes was assessed for progerin-
expressing cells, it was found that complex 1 activity was increased in these cells. Since 
complex 1 generates a large amount of the ROS (specifically the superoxide anion) 
produced by the mitochondria, its overactivation may play a role in the increased ROS-
related DNA damage observed in HGPS cells (Mateos et al., 2015). 
Nuclear factor erythroid 2-related factor 2 (NRF2) is a transcription factor for 
genes that code for antioxidant proteins involved in mediating the damage done by 
reactive oxygen species (ROS) generated within the cell. Progerin interferes with this 
pathway by altering NRF2’s subnuclear localization, sequestering the protein to itself and 
away from its target genes. Exogenous NRF2 expression alone was sufficient to restore 
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ROS levels to normal, suggesting NRF2 is the only protein in the transcription complex 
sequestered by progerin (Kubben et al., 2016). 
In some instances, the DNA repair proteins cannot enter the nucleoplasm to begin 
DNA damage repair. One such protein is 53bp1, which facilitates non-homologous end 
joining. Nup153, a nuclear pore complex (NPC) basket protein, is directly mislocalized to 
the cytoplasm by progerin (Busch et al., 2009). This contributes to the disrupted Ran 
gradient in HGPS cells. With loss of Nup153 on the NPCs, SENP1 is also mislocalized to 
the cytoplasm, which reduces sumoylation of 53bp1 (Duheron et al., 2017). Reduced 
sumoylation of 53bp1 and the disrupted Ran gradient work both inhibit entry of 53bp1 
into the nucleus, decreasing the ability of HGPS cells to perform NHEJ. 
To produce DNA damage repair proteins, the DNA that codes for these proteins 
must be unwound to allow their code to be turned into proteins. This is impaired in HGPS 
cells. The protein responsible for phosphorylating the protein KAP-1 in response to DNA 
damage, which then relaxes chromatin to encourage production of repair proteins, is 
downregulated in a mouse model of progeria. This downregulation delayed chromatin 
opening, thus impairing DNA repair (Liu et al., 2013). 
Two different major repair mechanisms are utilized by the cell to fix double-
stranded DNA breaks (DSBs): non-homologous end joining (NHEJ) and homologous 
recombination (HR). The decision to perform either NHEJ or HR is cell-cycle dependent; 
NHEJ is performed largely in G0/G1 phase, and HR in S/G2 phase (Escribano-Diaz et al, 
2013). Progerin induces changes in the cell that turn the decision on its head. In S/G2 
phase, HGPS cells have a strongly suppressed HR response, attributed to a lack of Rad51 
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recruitment. In addition, the NHEJ pathway is overly activated in S/G2 phase as a result 
of downregulation of PARP1, a NHEJ inhibitor, in HGPS SMCs (Zhang et al., 2014). 
Increase in error-prone NHEJ in S/G2 phase contributes to mitotic errors. Recruitment of 
RIF1, a regulator of NHEJ, was delayed in HGPS fibroblasts during G0/G1 phase, which 
may contribute to further dysregulation of NHEJ. It was also found that the over-
activation of NHEJ found in HGPS SMCs was not found in HGPS fibroblasts, implying a 
cell type-specific pathology (Zhang et al., 2016). 
One study that challenged the way scientists think about DNA damage is a study 
on the Nucleosome Remodeling Deacetylase (NuRD) complex. Originally, it was 
believed that DNA damage buildup lead to chromatin organizational defects. This study 
proposes that chromatin organizational defects may precede DNA damage accumulation. 
Two NuRD complex subunits, RBBP4 and RBBP7, are downregulated in HGPS cells. In 
wild-type cells with these subunits knocked down, levels of DNA modification, 
specifically H3K9me3 levels, dropped dramatically, consistent with what is observed in 
HGPS cells. These cells also showed more DNA damage foci, suggesting that disruption 
of the NuRD complex in HGPS cells is partially responsible for decreased DNA damage 
repair (Pegoraro et al., 2009). This study offers compelling evidence to implicate 
epigenetic changes and chromatin disorganization in the accumulation of DNA damage. 
How chromatin organization is disrupted in HGPS cells will be discussed further in this 
review. 
Mitotic Defects 
HGPS VASCULAR REVIEW  9 
Several mitotic defects have been reported in HGPS cells that could induce 
apoptosis or cellular senescence and contribute to VSMC loss and overall vascular 
disease. One such defect is in the machinery that performs replication during S phase. To 
understand how replication stress affects senescence, two studies recently published 
similar data to understand the role of progerin in collapsed replication forks at sites of 
DSBs. The first study identified sequestration of PCNA, a cofactor for DNA polymerase, 
to the nuclear periphery by progerin to be the cause of replication stress and reduced DSB 
repair. Without this cofactor, DNA polymerase replicated DNA much slower, and stalled 
more frequently, falling off the DNA strands (Wheaton et al., 2017). 
The second study was consistent with the first in identifying that PCNA is 
sequestered by progerin, but also identified XPA binding to stalled replication forks as a 
consequence of PCNA sequestration. XPA is a protein normally involved in nucleotide 
excision repair that binds specifically to the unique double strand/single strand junctions 
found at replication forks (Yang et al., 2006). This study also found that accumulations of 
XPA binding delayed the recruitment of repair factors to progerin-induced DSBs in 
HGPS cells. XPA binding also contributes to cell-cycle arrest, which in turn leads to 
cellular senescence and eventually apoptosis (Hilton et al., 2017).  
During and after mitosis, progerin also disrupts the nuclear localization of several 
lamina-associated proteins. Additionally, nuclear pore complexes were mislocalized in 
the same manner (Eisch et al., 2016). During mitosis, progerin forms insoluble aggregates 
in the cytoplasm that causes the abnormal distribution of these associated proteins (Cao et 
al., 2007). These aggregates cause the cell to spend more time trying to reform the 
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nuclear envelope and disrupt the arrangement of the envelope, which leads to more 
disrupted ability to communicate mechanical strain, which will be elaborated on later. 
HGPS cells also spend more time in anaphase than normal fibroblasts. This has 
been attributed to the slower localization of nuclear envelope proteins to the chromosome 
mass as well as impaired chromosome separation due to progerin competition for binding 
sites on the kinetochores. This extra time spent in anaphase is correlated with a higher 
percentage of binucleated cells and cells with giant nuclei in HGPS tissues (Eisch et al., 
2016). Such cells are developmentally arrested and undergo apoptosis. 
Chemical Modifications of Chromatin 
With new evidence supporting the idea that DNA damage is preceded by 
chromatin organizational changes, it is important to note the organizational changes that 
occur as a result of chemical modification of DNA in progerin-expressing cells. These 
modifications include both methylation and acetylation, as well as higher-level chromatin 
organizational changes. 
 Chromatin methylation defects are found in various loci on DNA histones, 
including both H3K9 and H3K27. On H3K9, there is an overall increase of methylation 
due to progerin binding to the methyltransferase Suv39h1 and protecting it from 
degradation. Increased methylation at this site physically prevents DNA damage repair 
proteins from reaching the site of DNA damage (Liu et al., 2013; Zheng et al., 2014). 
Methylation patterns at H3K27 were observed to be distinctly different from wild-type 
cells as well. Areas of high methylation were found to be hypomethylated in HGPS cells, 
and areas of low methylation were found to be hypermethylated in HGPS cells. These 
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areas of high and low methylation correspond to levels of gene expression being turned 
upside down in HGPS cells. Like H3K9 methylation, the methylatransferase associated 
with H3K27 methylation is affected by progerin expression: EZH2 is downregulated in 
HGPS cells (McCord et al., 2013; Shumaker et al., 2006).  
 Similarly, acetylation defects are observable in HGPS cells. One well-studied 
locus is H4K16. Acetylation of H4K16 is accomplished by the acetyltransferase Mof. As 
a result of progerin expression, Mof is mislocalized from the nuclear periphery, and 
hypoacetylation of H4K16 results (Krishnan et al., 2011). Autophagy is associated with 
deacetylation of H4K16, so the role of progerin in dysregulating autophagy is an area of 
further research (Füllgrabe et al., 2013). Consistent with reports of hypoacetylation of 
H4K16, both histones H2B and H4 were shown to be hypoacetylated in Zpmste24-null 
mice. H2B appears have hypoacetylation at lysine 5, and this hypoacetylation leads to 
downregulation of proliferation genes like Bcl6, Apcs, and Htatip2 (Osorio et al., 2010). 
 Lastly, higher-level organizational changes are observable in HGPS cells. 
Scenescence-associated distension of satellites (SADS) is the high-order unfolding of 
satellite heterochromatin and occurs in both naturally aging and HGPS cells. SADS is an 
early marker of replicative senescence, and it was shown to be occurring in fibroblasts of 
patients as young as one year old (Swanson et al., 2013). These findings confirm just how 
early HGPS fibroblasts enter cellular senescence and how important chromatin 
organization is in understanding the proliferation defects in HGPS. 
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Nuclear Response to Strain 
The presence of progerin in HGPS cell nuclei alter the way the nucleus reacts 
under mechanical strain. Specifically, HGPS laminas lack the ability to rearrange after 
mechanical stress. When exposed to mechanical stress, HGPS nuclei were slightly more 
resistant to rupture than wild-type fibroblast nuclei (Dahl et al., 2006). This resistance to 
rupture may be due in part to the fact that HGPS nuclei become increasingly stiff with 
age. However, these cells’ mechanosensitivity is increased, and they undergo apoptosis in 
response to normally tolerated levels of mechanical strain independent of increasing 
nuclear stiffness (Verstraeten et al., 2008). As vascular tissue is under constant stress, this 
could directly lead to VSMC loss via apoptosis. Additionally, the cells do not have the 
appropriate proliferation response to strain, as progerin inhibits cdk4 activity, impairing 
the cells’ Rb-mediated entry into S phase (Dechat et al., 2007). Senescence of HGPS 
VSMCs in response to strain would also contribute to vascular pathology. 
Studying the protein expression of cells from HGPS mice revealed that proteins 
involved in transduction of shear stress, namely the protein vimentin, were 
downregulated compared to wild-type cells (Song et al., 2014; Brassard et al., 2016). 
Vimentin is particularly important in reducing mechanosensitivity, as vimentin-free cells 
are extremely fragile (Goldman et al., 1996). When the effect of fluid sheer stress on cells 
was measured, HGPS cells exhibited decreased vimentin levels after just 30 minutes of 
stress (Song et al., 2014). With less vimentin, these cells are left vulnerable to rupture or 
apoptosis, contributing to VSMC loss.  
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Not only are there factors that contribute to VSMC loss in HGPS cells, but their 
ability to be replenished is also affected. One reason for this is a lack of proper 
communication of force to the nucleus. Using a novel biosensor in HGPS cells, 
Arsenovic et al. found that HGPS cells have reduced nuclear force, indicating an 
impaired ability to transfer cytonuclear mechanical forces (Arsenovic et al., 2016). With 
an impaired ability to sense mechanical force within the nucleus, those nuclear processes 
that are triggered by mechanical force would be disrupted (Athirasala et al., 2017). One 
such process is differentiation of stem cells within vascular tissue into either VSMCs or 
endothelial cells (Zhang et al., 2013). If this process were disrupted, it could provide 
insight into why lost VSMCs are not replaced. 
Telomere Dysfunction 
Telomeres in HGPS cells have been shown to be significantly shorter than their 
age matched counterparts (Decker et al., 2009). Shortened telomeres can induce cellular 
senescence and apoptosis, which would contribute to VSMC loss. How telomere 
disruption occurs and the mechanism by which it contributes to the pathology of HGPS is 
an area of much HGPS research, but three areas of focus will be covered for the sake of 
this review: DNA damage at telomeres, telomere mobility, and LAP2α association. 
 Whether telomere shortening or DNA damage came first in HGPS cells had been 
a question unanswered until recently, when ectopic progerin expression showed DNA 
damage foci localized to telomeres and induced abnormalities (Benson et al., 2010). It 
was also observed that progerin expressing cells form telomere aggregates, which are 
believed to be telomeric fusions. This could be a result of the faulty DDR mechanisms 
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engaging in NHEJ for damage telomeres. Why DNA damage localizes to telomeres has 
yet to be determined. 
One study performed a three-dimensional analysis of how telomeres move around 
within the nucleus. While knockout of lamin A/C caused mobility of telomeres to 
increase, HGPS cells showed decreased mobility of telomeres (De Vos et al., 2010). This 
provides evidence that proper binding to lamins is required for proper telomere dynamics. 
While the easy hypothesis is that progerin binds too tightly to telomeric complexes and 
maintains their position at the nuclear lamina, there is evidence that may challenge this 
hypothesis. TRF2, one subunit of the shelterin complex that helps telomeres adapt their 
T-loop formation and is specifically involved in telomere binding to lamins, was found to 
have a decreased binding affinity for progerin (Wood et al., 2014).  
Lastly, LAP2α is a binding partner of lamin A that binds with a lower affinity to 
progerin. It has also come to light that LAP2α directly interacts with telomeres. In HGPS 
cells however, the interaction between the telomere and LAP2α is physically further apart 
by about 200 nm (Chojnowski et al., 2015). How this interaction affects cell proliferation 
is still unknown, but it has been shown that introduction of ectopic telomerase rescues 
DNA damage and other proliferative defects in HGPS cells (Kudlow et al., 2008). 
Decreased Cell Motility 
A reason VSMCs may not be replaced after undergoing apoptosis is that migration of 
HGPS cells is severely impaired. A study by Booth-Gauthier showed that HGPS cells’ 
mobility through a micropillar array was severely limited compared to normal cells. 
When examined with traction force microscopy, HGPS cells exerted less than half the 
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traction force of control cells, because of their weaker ability to generate force within the 
cell (Booth-Gauthier et al., 2013). Additionally, the ability for microtubules to generate 
force in progerin-expressing cells is disrupted. The processes which rely on microtubules, 
such as migration, are thusly impaired (Tariq et al., 2017).  With the ECM of HGPS cells 
already stiffer than usual, their inability to navigate tight interstitia may contribute to 
decreased cell replenishment.  
Lack of Stem Cell Population 
A final issue in VSMC replenishment in HGPS patients is the lack of a healthily 
maintained population of immature stem cells from which to draw for things like wound 
healing and vascular repair. To properly execute vascular repair, the immature stem cell 
population must be available, they must be able to detect that damage has occurred, 
migrate through the bloodstream to the site of damage, and differentiate into the 
necessary cell lineage for the repair. The ability of these cells to self-renew has been 
shown to be decreased in progerin-expressing cells (Pacheco et al., 2014). 
Vascular Calcification 
In addition to extensive VSMC loss, analysis also shows extensive fibrosis and 
calcification of the walls of the aortic walls of HGPS patients. One study on vascular 
calcification found that two anticalcification agents, MGP and fetuin A, were not 
downregulated in progerin-expressing cells, but that levels of extracellular pyrophosphate 
(ePPi) were drastically lower in progerin-expressing cells. As ePPi is an inhibitor of 
calcification, these lower levels of ePPi suggest a causative link to increased calcification. 
The cause of this appears to be the result of many factors. Progerin-expressing cells 
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exhibit upregulation of the enzyme that hydrolyzes ePPi (TNAP) and the enzyme 
involved in hydrolysis of ATP to produce Pi, along with overall decreased production of 
ATP due to mitochondrial dysfunction of complex IV. Treatment with PPi was able to 
prohibit aortic calcification in the mouse model of HGPS (Villa-Bellosta et al., 2013). 
Additionally, another study linked increased DNA damage, specifically activation 
of ATM/ATR signaling, and the senescence-associated secretory phenotype (SASP) to 
increased vascular calcification and osteogenesis in the presence of prelamin A (Liu et 
al., 2013). It appears that both increased calcification from this study and the lack of an 
inhibitory pathway (ePPi) contribute to the increased vascular calcification observed in 
HGPS patients. 
Atherosclerosis 
Vascular stiffening is one of the most common symptoms associated with HGPS 
patients. Compared to normal aging, fibrosis of the vessel walls is worse than most 
geriatric patients, specifically in the adventitial layers (Gerhard-Herman et al., 2012). 
Several factors may contribute to this phenomenon, including transcription factor 
dysregulation, stem cell differentiation dysregulation, and ECM dysregulation. While 
many transcription factors are dysregulated in HGPS cells, a few are relevant to 
atherosclerosis development. 
NF-kB, a transcription factor that controls cell proliferation and survival, is 
chronically overactive in a mouse model of progeria (Osorio et al., 2012). Inhibition of 
NF-kB or its downstream targets alleviates symptoms of aging in mouse models (Osorio 
et al., 2012, Soria-Valles et al., 2015). Hyperactivation of  NF-kB contributes to 
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senescence-associated secretory phenotype (SASP). SASP is a collection of secretions 
that can cause inflammatory response and reduce the ability of the immune system to 
properly scavenge for senescent cells for removal (Salminen et al., 2012). Increased 
inflammation would worsen atherosclerosis and prevent migration of healing response to 
the tissues. 
Wild-type lamin A regulates the movement of SKIP, a co-activator of Notch, to 
the nucleus by retaining it at the nuclear lamina. This regulation is defective in cells 
containing progerin, as HGPS cells have significant loss of SKIP from the nuclear 
lamina, indicating that progerin’s ability to sequester SKIP to the lamina is lost and that 
most SKIP makes it to the DNA to activate Notch (Scaffidi et al., 2008). Increased Notch 
is a known dysregulator of stem cell differentiation. 
Dysregulation of stem cell differentiation is another factor that could play a role 
in atherosclerosis. In MSCs, expression of progerin causes these cells to express low 
levels of differentiation markers and tissue-specific markers such as collagen IV and 
MCAM. Expression of these markers affects downstream differentiation. Of interest, 
osteocyte differentiation is enhanced in HGPS cells (Scaffidi et al., 2008). Increased 
osteocyte differentiation in HGPS MSCs, specifically VSMCs, would only worsen 
atherosclerosis. 
A final factor that may contribute to atherosclerosis in HGPS cells is the 
dysregulation of ECM proteins. Of interest particular interest with respect to 
atherosclerosis are collagen expression and MMP-3 expression. In a protein analysis of 
HGPS cells, type 6 collagen and fibronectin were both found to be upregulated two-fold 
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(Song et al., 2014). This has implications in many molecular pathologies of HGPS, and 
specifically in the development of cardiovascular disease. Increased levels of collagen 
would lead to a stiffer and less elastic ECM in cardiac tissue, which would lead to overall 
increased stiffness of the vasculature. 
In addition to dysregulated secretions of ECM proteins, the enzymes involved in 
remodeling these proteins are dysregulated in progerin-expressing cells. Matrix 
metalloproteinase 3 (MMP-3) is one such remodeling enzyme affected in HGPS cells. 
This enzyme can break down basement membrane components including proteoglycans – 
which have been found in place of VSMCs in aortic tissue (Villa-Bellosta et al., 2013) – 
as well as collagens (Okada et al., 1986). In HGPS cells, both mRNA and protein levels 
of MMP-3 decrease with patient age (Harten et al., 2011). Without the ability to remodel 
the ECM, atherosclerosis cannot be alleviated with the cells’ own machinery. 
With increased atherosclerosis, thickening of the adventitia may affect migration 
of immune cells from the blood, past the endothelium, and into vessel walls (Han et al., 
201; Song et al., 2016), thus preventing alleviation of atherosclerosis by immune cells. 
Contractility 
Electrocardiograms of HGPS patients show defects in electrical conduction that 
worsen with disease progression. A study of progeroid mouse model cardiomyocytes 
showed mislocalization of gap junction protein connexin 43, which is necessary for 
maintaining proper action potential conduction between cells (Rivera-Torres et al., 2016). 
In addition to electrical conduction, the ability of HGPS patients’ hearts to 
contract with full force may be limited by mitochondrial dysfunction in the cells of the 
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heart walls. Observation of HGPS fibroblasts revealed enlarged and fragmented 
mitochondria that exhibited limited movement compared to wild-type mitochondria 
(Xiong et al., 2016). What causes the mitochondria to be enlarged and fragmented is 
unknown, but it has been observed that these cells have downregulated proteins 
responsible for ATP production. 
These downregulated proteins affect the cytochrome b-c1 complex (complex III) 
(Song et al., 2014), cytochrome c, cytochrome c oxidase (complex IV) (Mateos et al., 
2015), and proteins for ATP synthase. Additionally, the mitochondrial membrane 
potential of HGPS cells was disrupted, which would directly hamper ATP production in 
these cells (Xiong et al., 2016). With ATP production affected in these cells, the energy 
required for repeated contraction of the heart is low and may inhibit full contractile force. 
Treatments 
 The effects of progerin on cellular machinery are far-reaching. So many facets of 
cellular maintenance are affected in HGPS cells, which is why so many types of 
treatment strategies have been proposed and explored. With the various categories of 
vascular pathologies explored in this review, categories of treatment are also discussed. 
First, the most well-studied treatment approach, farnesyl transferase inhibitors, will be 
covered. Next, studies involving induced pluripotent stem cells will be discussed, 
followed by various treatments targeting specific aspects of pathology. These treatments 
fall roughly into two categories: those that prevent DNA damage and those that induce 
autophagy. Finally, treatments that focus on preventing progerin expression will be 
discussed. 
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FTIs 
 One of the first approaches to treating HGPS was the use of farnesyl transferase 
inhibitors (FTIs). It had been shown that FTIs alleviated the nuclear abnormalities 
associated with HGPS (Capell et al., 2005). The first clinical trial utilized the FTI 
lonafarnib for two years (Gordon et al., 2012). During this first trial, the incidence of 
headaches amongst patients decreased significantly, as well as the incidence of TIAs and 
seizures (Ullrich et al., 2013). After the first trial, a second clinical trial incorporated 
pravastatin to inhibit HMG-CoA and zoledronate to inhibit farnesyl-pyrophosphate 
synthase (Varela et al., 2008). The combination of these trials saw improvement in 
lifespan, with an estimated average increase of 1.6 years (Gordon et al., 2014).  
 Several issues have been raised with the use of FTIs. One is that the therapy has 
limited efficacy. The evidence shows that despite alleviating nuclear abnormalities, 
unfarnesylated progerin can still cause disease phenotypes (Yang et al., 2008). 
Additionally, treatment with FTIs prevents farnesylation of all proteins, including those 
whose farnesylation is required for homeostasis. Thus, abnormal, “donut-shaped” nuclei 
appear upon treatment with FTIs that can be attributed to an indirect effect on pericentrin, 
a centrosome protein (Verstraeten et al., 2011). 
 Recently a new class of farnesyl modulators, aminopyrimidines, have been 
discovered in a high throughput screening. Monoaminopyrimidines showed alleviation of 
nuclear abnormalities with limited side effects (Blondel et al., 2016). Further exploration 
of these compounds must be done to evaluate them for therapeutic use. 
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iPSCs 
 Induced pluripotent stem cells continue to be helpful in studying the effects of 
treatments on HGPS cells. A study by Blondel et al. used MSCs derived from HGPS 
iPSCs to evaluate the effect of three compounds currently being used in clinical trials 
(Bondel et al., 2014). The benefit to using iPSCs derived from HGPS patients is that 
while they still carry the mutation, inducing the HGPS fibroblasts “resets” the cells to 
conditions comparable to WT counterparts, including the epigenetic differences between 
WT and HGPS cells (Chen et al., 2017). 
Along similar lines, one study observed the effect of injecting muscle-derived 
stem/progenitor cells from young, healthy mice into the peritoneum of older progeroid 
mice. Culturing the MDSPCs from the young mice improved the function of the old 
progeroid MDSPCs, implying an external causative factor that can be reversed to restore 
function (Lavasani et al., 2012). Other adult stem cell types could be investigated to see 
whether stem cell therapy may improve vascular function. 
Therapies That Alleviate DNA Damage 
 Several compounds have been identified as potential therapeutic strategies for 
managing the symptoms of HGPS, specifically targeting DNA damage. While treatment 
with the molecule remodelin aims to restore localization of DNA damage repair proteins, 
the rest of these therapies focus on reducing ROS produced by faulty mitochondria in 
HGPS cells. These treatments include the molecules methylene blue, metformin, Y-
27632, and N-acetyl cysteine. 
Remodelin 
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With what is known about DNA damage repair protein mislocalization, the small 
molecule remodelin (Cobb et al., 2016) was shown to restore localization of Nup153 by 
inhibiting the N-acetyl-transferase NAT10 (Larrieu et al., 2014). Relocalization of 
Nup153 restored entry of 53bp1 into the nucleus to promote NHEJ and lessened DNA 
damage in aged VSMCs. 
Methylene Blue 
In investigating mitochondrial dysfunction in HGPS cells, methylene blue was 
used to alleviate the ROS-related damage due to its known antioxidant properties. 
Interestingly, it not only restored mitochondrial properties, but also alleviated nuclear 
blebbing, released some progerin to the nucleoplasm, restored pericentric 
heterochromatin organization, and restored some gene expression to near WT levels 
(Xiong et al., 2016). The numerous positive effects methylene blue had on HGPS cells 
makes it an interesting candidate for combination therapy.  
Metformin 
The effects of metformin on HGPS fibroblasts were analyzed and produced 
promising results. Like many compounds, metformin rescued nuclear deformations. 
Treatment with metformin reduced formation of DNA damage markers, reduced 
superoxide formation in mitochondria, helped clear progerin from the cells in a manner 
that may activate autophagy pathways (Park and Shin, 2017). Reducing ROS damage 
would help prevent VSMC loss. One study showed that and added benefit of treatment 
with metformin is that it could prevent premature osteogenic differentiation, which would 
help alleviate atherosclerosis in HGPS patients (Egesipe et al., 2016). Metformin is a 
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good candidate for treatment as it is relatively inexpensive and is already commonly used 
to treat diabetes. 
Y - 27632 
 A HT screening revealed rho-associated protein kinase (ROCK) inhibitor (Y-
27632) as a useful compound for modulating mitochondrial ROS levels. ROCK decreases 
the activity of cytochrome c oxidase by modulating the interaction between rac1b and 
cytochrome c. Inhibition of ROCK with Y-27632 decreased ROS levels, rescued nuclear 
abnormalities, and decreased formation of DNA damage markers (Kang et al., 2017).  
N-acetyl Cysteine 
High ROS levels in HGPS cells are associated with DNA damage, loss of 
heterochromatin, and proliferation defects (Richards et al., 2011). These proliferation 
defects can be alleviated with N-acetyl cysteine (NAC), which has also been shown to 
synergize with statins, making a combination therapy an attractive possibility (Richards 
et al., 2011; Biswas et al., 2011). 
Therapies That Induce Autophagy 
Rapamycin/All-trans Retanoic Acid 
Several studies have identified clearance of progerin via activation of autophagy 
by introduction of rapamycin (Cenni et al., 2011; Cao et al., 2011). Further investigation 
of the mechanism of rapamycin showed that autophagy of progerin is lysosome 
dependent, and rapamycin treatment helped increase progerin solubility to help with 
clearance (Cao et al., 2011). This is consistent with reports that progerin is more resistant 
to degradation than wild-type lamin A (Wu et al., 2016). Variants of rapamycin have 
HGPS VASCULAR REVIEW  24 
been identified (Gabriel et al., 2017; Gabriel et al., 2015), and other autophagy inducers 
are currently being studied (Harhouri et al., 2017). A clinical trial is underway now to 
observe the combined effects of lonafarnib and everolimus, a rapamycin analog. 
Combining rapamycin treatment with all-trans retinoic acid increased progerin clearance 
while also decreasing mRNA transcripts of progerin, an improvement from treatment 
with rapamycin alone (Pellegrini et al., 2015). 
Splicing Variants and SRSFs  
Ultimately, decreasing expression of progerin and promoting wild-type lamin A 
expression is the goal when it comes to treating HGPS. Prohibiting the production of 
progerin would curtail the pathologies that it is responsible for. Several approaches to 
changing the splicing of the LMNA gene have been studied, including modified 
oligonucleotides and controlling expression of endogenous splicing factors within the 
cell. 
Modified Oligonucleotides 
Using a modified oligonucleotide complimentary to the region of the LMNA gene 
where the progerin mutation is found, expression of progerin was sufficiently blocked to 
restore normal phenotype to HGPS cells. This includes restoration of abnormal 
expression of ECM proteins and histone modifications as well as nuclear membrane 
kinetics and nuclear shape (Scaffidi and Mistelli, 2005). 
Based on this study, two modified oligonucleotides, one targeting exon 10 and 
another exon 11, were created and administered to progerin knock-in mice. While both 
morpholinos reduced progerin levels individually, the administration of both morpholinos 
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reduced progerin expression to near zero (Osorio et al., 2011). Another modified 
oligotide was developed by Lee’s lab that targeted exon 11 and shifted LMNA splicing 
toward lamin C and ameliorated aortic pathology in progeroid mice (Lee et al., 2016). 
Two independent studies confirmed the presence of an endogenous microRNA 
specific to neuronal tissue that inhibits the expression of progerin. This microRNA did 
not affect expression of lamin C in Zmpste24-null neuronal tissue, but effectively 
silenced lamin A production. The only places in the brain where cells expressed lamin A 
were in the vasculature and the meninges (Jung et al., 2012). When HGPS iPSC-derived 
MSCs were treated with miR-9, progerin levels decreased drastically (Nissan et al., 
2012). Whether this could be considered as a viable treatment option would depend on 
developing a mechanism of delivery, and how different cell types’ functionality would be 
impacted by expression of only lamin C. 
SRSFs 
One study showed that increased expression of SRSF5, a splicing factor, could 
alter the splicing of the LMNA gene. Transfecting HGPS fibroblasts with exogenous 
SRSF5 was sufficient to shift splicing in favor of wild-type lamin A. To test a method 
that didn’t involve direct transfection, the growth factor PDGF-BB was introduced. This 
growth factor increased activation of SRSF5 by phosphorylating Akt. Introduction of 
PDGF-BB reduced the ratio of progerin to lamin A by 30% (Vautrot et al., 2015). 
Additionally, SRSF1 and SRSF6 have shown to have roles in progerin splicing as 
well. Knockdown of SRSF6 increased the amount of progerin mRNA produced and 
slightly lowered the amount of lamin A mRNA produced. SRSF1 knockdown slightly 
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reduced the amount of progerin mRNA produced but did not affect lamin A production 
(Lopez-Mejia et al., 2011). Further analysis of the potential use of increased activity of 
SRSF6/downregulation of SRSF1 could be performed to assess therapeutic use. 
Conclusions 
 The cellular mechanisms driving the premature aging disorder Hutchinson-
Gilford Progeria Syndrome are as complex as the nuclear machinery itself. With just a 
single point mutation, hundreds of protein-protein interactions, transcription factors, and 
chromatin modifiers are disrupted, leaving the nucleus scrambling to continue 
proliferating. The most deeply affected tissues in HGPS are vascular tissues. 
Understanding the mechanisms by which the vasculature pathology develops will help 
the scientific community to better treat HGPS patients. This review has covered the four 
main categories of vascular pathology in HGPS patients: vascular smooth muscle cell 
loss, vascular calcification, atherosclerosis, and contractility defects. It has also discussed 
treatment strategies relevant to these pathologies. Together, scientists from numerous 
countries have joined in the research of this premature aging disorder to unlock its 
implications for natural human aging and provide relief for those suffering from this 
disease. 
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